MYGN

Myriad Genetics Inc

Add to Watchlist

Advanced Chart

3.890

-0.140(-3.470%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

4.230

Open

4.090

VWAP

3.97

Vol

3.87M

Mkt Cap

358.57M

Low

3.860

Amount

15.36M

EV/EBITDA(TTM)

Total Shares

90.51M

338.97M

EV/OCF(TTM)

P/S(TTM)

0.44

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.

14 Analyst Rating

279.69% Upside

Wall Street analysts forecast MYGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYGN is 14.77 USD with a low forecast of 9.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

5 Hold

3 Sell

Hold

279.69% Upside

Current: 3.890

Low

9.00

Averages

14.77

High

22.00

279.69% Upside

Current: 3.890

Low

9.00

Averages

14.77

High

22.00

Wells Fargo

Brandon Couillard

Buy

Hold

Downgrades

$22 → $6

2025-05-08

New

Reason

Wells Fargo

Brandon Couillard

Price Target

$22 → $6

2025-05-08

New

Downgrades

Buy

Hold

Reason

Goldman Sachs

Matthew Sykes

Strong Buy

Maintains

$18 → $14

2025-04-17

Reason

Goldman Sachs

Matthew Sykes

Price Target

$18 → $14

2025-04-17

Maintains

Strong Buy

Reason

Guggenheim

Subbu Nambi

Strong Buy

Hold

Downgrades

n/a

2025-04-09

Reason

Guggenheim

Subbu Nambi

Price Target

n/a

2025-04-09

Downgrades

Strong Buy

Hold

Reason

Guggenheim downgraded Myriad Genetics to Neutral from Buy without a price target. Based on key opinion leader checks on GeneSight and Prolaris, the firm cut estimates for both GeneSight and Prolaris. The analyst cites price compression for Genesight and lower Prolaris volume growth due to competitive pressures for the downgrade. Prolaris is losing market share in prostate cancer risk stratification and will not continue to grow in the foreseeable future, the analyst tells investors in a research note.

Scotiabank

Sung Ji Nam

Buy

Maintains

$24 → $20

2025-04-01

Reason

Scotiabank

Sung Ji Nam

Price Target

$24 → $20

2025-04-01

Maintains

Buy

Reason

Scotiabank lowered the firm's price target on Myriad Genetics to $20 from $24 and keeps an Outperform rating on the shares. The firm believes Myriad Genetics continued efforts to strengthen its Oncology and Women's Health businesses and its operating efficiency well-position the company to reaccelerate growth and further improve its profitability profile in 2026 and beyond, the analyst tells investors.

Piper Sandler

Dave Weiner

Hold

Buy

Upgrades

$12 → $13

2025-03-12

Reason

Piper Sandler

Dave Weiner

Price Target

$12 → $13

2025-03-12

Upgrades

Hold

Buy

Reason

Piper Sandler upgraded Myriad Genetics to Overweight from Neutral with a price target of $12.50, up from $11.50. The stock is down more than 50% in the last six months and Myriad still has a leading position and high margins in markets that are consolidating around a "profitability paradigm," the analyst tells investors in a research note. Piper believes the stock "has more than rebased" and the new CEO Sam Raha has a chance to reset the business, make strategic decisions and "provide reasonable expectations to match."

Piper Sandler

Dave Weiner

Hold

Maintains

$14 → $12

2025-03-04

Reason

Piper Sandler

Dave Weiner

Price Target

$14 → $12

2025-03-04

Maintains

Hold

Reason

Piper Sandler lowered the firm's price target on Myriad Genetics to $11.50 from $14 following quarterly results. The firm keeps a Neutral rating on the shares.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Myriad Genetics Inc (MYGN.O) is 146.55, compared to its 5-year average forward P/E of -39.04. For a more detailed relative valuation and DCF analysis to assess Myriad Genetics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-39.04

Current PE

146.55

Overvalued PE

392.19

Undervalued PE

-470.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

37.11

Current EV/EBITDA

16.69

Overvalued EV/EBITDA

122.78

Undervalued EV/EBITDA

-48.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

2.39

Current PS

0.48

Overvalued PS

3.14

Undervalued PS

1.64

Financials

Annual

Quarterly

FY2025Q1

YoY :

-3.12%

195.90M

Total Revenue

FY2025Q1

YoY :

-0.34%

-29.00M

Operating Profit

FY2025Q1

YoY :

-99.62%

-100.00K

Net Income after Tax

FY2025Q1

YoY :

-100.00%

0.00

EPS - Diluted

FY2025Q1

YoY :

-9.56%

-24.60M

Free Cash Flow

FY2025Q1

YoY :

+0.66%

68.50

Gross Profit Margin - %

FY2025Q1

-4.31

FCF Margin - %

FY2025Q1

YoY :

-99.61%

-0.05

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

2.4M

USD

0-12

Months

698.1K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 662.8% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

850.0K

Volume

6-9

Months

0.0

Volume

0-12

Months

6.7M

Volume

Bought

0-3

0.0

Volume

Months

3-6

2.9M

Volume

Months

6-9

0.0

Volume

Months

0-12

384.0K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

2.4M

USD

0-12

Months

698.1K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

MYGN News & Events

Events Timeline

2025-05-06 (ET)

2025-05-06

17:00:05

Myriad Genetics cuts FY25 adjusted EPS view to (2c)-2c from 7c-11c

2025-05-06

16:57:24

Myriad Genetics reports Q1 adjusted EPS (3c), consensus (5c)

2025-04-21 (ET)

2025-04-21

16:08:53

Myriad says GeneSight Psychotropic Test led to fewer hospitalizations in study

News

9.0

05-07Newsfilter

PinnedMyriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

6.5

05-07Benzinga

What Analysts Are Saying About Myriad Genetics Stock

6.0

05-07Benzinga

Goldman Sachs Maintains Buy on Myriad Genetics, Lowers Price Target to $8

People Also Watch

HCM II Acquisition Corp

Launch One Acquisition Corp

Artesian Resources Corp

Iteos Therapeutics Inc

Lanvin Group Holdings Ltd

2.470

USD

+11.26%

FAQ

What is Myriad Genetics Inc (MYGN) stock price today?

The current price of MYGN is 3.89 USD — it has decreased -3.47 % in the last trading day.

MYGN

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

MYGN News & Events

Events Timeline

News

People Also Watch

FAQ

What is Myriad Genetics Inc (MYGN) stock price today?

What is Myriad Genetics Inc (MYGN)'s business?

What is the price predicton of MYGN Stock?

What is Myriad Genetics Inc (MYGN)'s revenue for the last quarter?

What is Myriad Genetics Inc (MYGN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Myriad Genetics Inc (MYGN)'s fundamentals?

How many employees does Myriad Genetics Inc (MYGN). have?

What is Myriad Genetics Inc (MYGN) market cap?